A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (<i>FLT3</i>)‐mutated acute myeloid leukemia
A FLT3i and allogeneic stem cell transplantation are key treatment modalities for patients who have FLT3-mutated AML. LIT-based triplets are promising in IC-ineligible patients.
Authors
- Courtney Denton Dinardo (ORCID: https://orcid.org/0000-0001-9003-0390)
- Tapan Mahendra Kadia (ORCID: https://orcid.org/0000-0002-9892-9832)
- Koji Sasaki (ORCID: https://orcid.org/0000-0002-9140-0610)
- Álex Bataller (ORCID: https://orcid.org/0000-0002-6085-2745)
- Naval Guastad Daver (ORCID: https://orcid.org/0000-0001-7103-373X)
- Ian Bouligny (ORCID: https://orcid.org/0000-0002-4274-4249)
- Musa E. Yilmaz (ORCID: https://orcid.org/0000-0002-4498-4895)
- Gautam M. Borthakur (ORCID: https://orcid.org/0000-0001-7679-6453)
- Alexandre Bazinet (ORCID: https://orcid.org/0000-0001-5538-4943)
- Guillermo Garcia‐Manero (ORCID: https://orcid.org/0000-0002-3631-2482)
- Farhad Ravandi
- Ghayas C. Issa
- Hagop M. Kantarjian (ORCID: https://orcid.org/0000-0002-1908-3307)
- Nicholas James Short (ORCID: https://orcid.org/0000-0002-2983-2738)
- Sherry Pierce
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-03-15
- DOI
- https://doi.org/10.1002/cncr.35813
- Citations
- 7
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 12.39